Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis
Since its discovery, small interfering RNA (siRNA) has been considered a potent tool for modulating gene expression. It has the ability to specifically target proteins via selective degradation of messenger RNA (mRNA) not easily accessed by conventional drugs. Hence, RNA interference (RNAi) therapeu...
Main Authors: | Fatima Khaja, Dulari Jayawardena, Antonina Kuzmis, Hayat Önyüksel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-01-01
|
Series: | Nanomaterials |
Subjects: | |
Online Access: | http://www.mdpi.com/2079-4991/6/1/8 |
Similar Items
-
Targeted delivery of BMP4-siRNA to hepatic stellate cells for treatment of liver fibrosis
by: Omar, Refaat
Published: (2015) -
Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing
by: Elisabeth H. Vollmann, et al.
Published: (2017-06-01) -
Specific siRNA Targeting the Receptor for Advanced Glycation End Products Inhibits Experimental Hepatic Fibrosis in Rats
by: Nai-Xun Zhu, et al.
Published: (2008-04-01) -
Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery
by: Wanyi Tai
Published: (2019-06-01) -
Self-Assembling β-Glucan Nanomedicine for the Delivery of siRNA
by: Kyungwoo Lee, et al.
Published: (2020-11-01)